Published in J Clin Oncol on June 01, 2001
Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites | NCT01377324
Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET | NCT03065712
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.50
Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging (2006) 1.47
A clash of old and new scientific concepts in toxicity, with important implications for public health. Environ Health Perspect (2009) 1.39
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res (2009) 1.24
The role of PET in monitoring therapy. Cancer Imaging (2005) 1.17
Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography. Breast Cancer Res (2005) 1.16
Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med (2007) 1.10
Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology. Nucl Med Mol Imaging (2014) 1.08
Monitoring therapeutic efficacy in breast carcinomas. Eur Radiol (2006) 1.03
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med (2011) 1.02
Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging (2004) 1.02
Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET. J Ovarian Res (2009) 1.02
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. Eur J Nucl Med Mol Imaging (2004) 0.99
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res (2011) 0.98
Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer Imaging (2011) 0.97
Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V. Proc Am Thorac Soc (2009) 0.96
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands. J Med Chem (2011) 0.95
Future directions for the early detection of recurrent breast cancer. J Cancer (2014) 0.95
Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med (2012) 0.94
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist (2015) 0.92
Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione. J Nucl Med (2012) 0.92
Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma. PLoS One (2013) 0.90
Integrin imaging to evaluate treatment response. Theranostics (2011) 0.89
Advances in molecular imaging for breast cancer detection and characterization. Breast Cancer Res (2012) 0.89
Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. Acad Radiol (2007) 0.89
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol (2013) 0.87
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PLoS One (2014) 0.86
Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res (2012) 0.86
Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. Nucl Med Biol (2008) 0.85
Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation. Mol Imaging Biol (2012) 0.85
18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer. J Nucl Med (2016) 0.84
Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. J Med Chem (2010) 0.84
Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging (2008) 0.84
The role of SPET and PET in monitoring tumour response to therapy. Eur J Nucl Med Mol Imaging (2003) 0.84
Positron Emission Tomography in Breast Cancer. Diagnostics (Basel) (2015) 0.81
Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm. Cancer Imaging (2010) 0.81
Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging (2007) 0.80
Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med (2013) 0.79
Predicting Breast Cancer Endocrine Responsiveness Using Molecular Imaging. Curr Breast Cancer Rep (2011) 0.79
[F]fluoro-2-deoxy-d-glucose incorporation by mcf-7 breast tumour cells in vitro is modulated by treatment with tamoxifen, Doxorubicin, and docetaxel: relationship to chemotherapy-induced changes in ATP content, hexokinase activity, and glucose transport. Int J Mol Imaging (2010) 0.79
Molecular imaging as a tool for translating breast cancer science. Breast Cancer Res (2008) 0.79
Utility of (18)F-fluoroestradiol ((18)F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy. Eur J Nucl Med Mol Imaging (2016) 0.78
Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy. Clin Cancer Res (2014) 0.77
Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med (2016) 0.77
Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. Eur J Nucl Med Mol Imaging (2015) 0.76
A study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts. NMR Biomed (2015) 0.76
Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target. Nucl Med Biol (2012) 0.76
Metabolic flare phenomenon on 18 fluoride-fluorodeoxy glucose positron emission tomography-computed tomography scans in a patient with bilateral breast cancer treated with second-line chemotherapy and bevacizumab. Indian J Nucl Med (2015) 0.75
Hypermetabolic Calcified Lymph Nodes on 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomography in a Case of Treated Ovarian Cancer Recurrence: Residual Disease or Benign Formation? Mol Imaging Radionucl Ther (2016) 0.75
Review: Receptor Targeted Nuclear Imaging of Breast Cancer. Int J Mol Sci (2017) 0.75
Precision Medicine and PET/Computed Tomography: Challenges and Implementation. PET Clin (2016) 0.75
Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapy. Breast Cancer Res (2003) 0.75
Development of Companion Diagnostics. Semin Nucl Med (2016) 0.75
The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. Br J Cancer (2015) 0.75
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res (2016) 0.75
Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES. Br J Radiol (2012) 0.75
Assessment of therapy response in malignant tumours with 18F-fluorothymidine. Eur J Nucl Med Mol Imaging (2007) 0.75
Early Metabolic Flare in Squamous Cell Carcinoma after Chemotherapy is a Marker of Treatment Sensitivity In Vitro. Nucl Med Mol Imaging (2010) 0.75
Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients? Eur J Nucl Med Mol Imaging (2012) 0.75
Molecular imaging-its current role in cancer. QJM (2015) 0.75
Special Relevance of FDG-PET as an Upfront Diagnostic Modality at Initial Diagnosis and in Suspected Recurrence in Patients of Breast Carcinoma Hailing From Lower Socioeconomic Status Owing to Relative Late Presentation: A Pilot Study in a Medical College Hospital Setting in India. Indian J Surg Oncol (2014) 0.75
Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases. Eur J Nucl Med Mol Imaging (2005) 0.75
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A (1986) 4.51
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem (2000) 3.34
Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol (1997) 3.25
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol (1984) 3.11
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg (2001) 2.40
Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology (2008) 2.33
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry (1997) 2.32
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000) 2.30
Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. Arch Ophthalmol (2001) 2.30
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2001) 2.15
FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol (2000) 1.96
Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev (1999) 1.93
Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology (1999) 1.93
Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol (1983) 1.88
Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med (1977) 1.87
Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med (1982) 1.85
The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids (1997) 1.80
64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med (2001) 1.80
Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol (1997) 1.77
Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med (1990) 1.77
Functional consequences of posttranslational isomerization of Ser46 in a calcium channel toxin. Science (1994) 1.73
Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res (2000) 1.69
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A (2000) 1.69
Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry (1973) 1.67
Evidence that phospholipase A2 activity is required for Golgi complex and trans Golgi network membrane tubulation. Proc Natl Acad Sci U S A (1998) 1.65
Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol (2001) 1.64
Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med (1999) 1.62
Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res (1976) 1.61
Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery (2001) 1.57
Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med (1993) 1.56
Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med (1983) 1.55
Breast cancer: PET imaging of estrogen receptors. Radiology (1988) 1.53
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology (2009) 1.52
The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol (1998) 1.52
Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med (2001) 1.51
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology (2000) 1.50
Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med (1999) 1.49
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology (1987) 1.49
Blood-brain barrier permeability of 11C-labeled alcohols and 15O-labeled water. Am J Physiol (1976) 1.48
In vivo comparison of copper blood-pool agents: potential radiopharmaceuticals for use with copper-62. J Nucl Med (1991) 1.46
Ventilation-perfusion studies in suspected pulmonary embolism. AJR Am J Roentgenol (1979) 1.45
Elevations of CK-MB following pulmonary embolism. A manifestation of occult right ventricular infarction. Chest (1992) 1.44
In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol (1990) 1.42
Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem (1982) 1.41
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol (1997) 1.40
Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res (1979) 1.39
Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol (2001) 1.39
Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol (1999) 1.39
Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant (2000) 1.39
Zearalenones: characterization of the estrogenic potencies and receptor interactions of a series of fungal beta-resorcylic acid lactones. Endocrinology (1979) 1.36
Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs. Radiology (1976) 1.36
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res (1996) 1.35
Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology (2010) 1.35
Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med (1995) 1.34
Diffusible Factors Essential for Epidermal Cell Redifferentiaion in Catharanthus roseus. Science (1989) 1.33
Alterations in the morphology of lamina cribrosa pores in glaucomatous eyes. Br J Ophthalmol (2004) 1.31
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg (1998) 1.30
Copper-64-labeled antibodies for PET imaging. J Nucl Med (1992) 1.29
Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res (2000) 1.29
Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J Med Chem (1994) 1.29
Tuberculous peritonitis--report of 30 cases and review of the literature. Q J Med (1985) 1.28
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology (2010) 1.26
Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler (2006) 1.25
Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum (2000) 1.25
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med (2001) 1.25
Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology (2010) 1.24
Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology (1993) 1.24
Quantification of regional myocardial blood flow in vivo with H215O. Circulation (1984) 1.24
Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine. J Biol Chem (1983) 1.24
Vocal cord dysfunction in a child with asthma. J Asthma (1991) 1.23
RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med (1995) 1.21
Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med (1991) 1.21
Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Proc Natl Acad Sci U S A (1996) 1.20